ArticleNature medicine2004
Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques.
Article in Nature medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 239 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
239 citing papers in PubMed, 3 syntheses or guidelines pooled it, 387 citations in OpenAlex.
- COVID-19 pandemic: insights into molecular mechanisms leading to sex-based differences in patient outcomes.Expert reviews in molecular medicine · 2021Pooled it
- Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review ofTheranostics · 2021Pooled it
- Potential interventions for novel coronavirus in China: A systematic review.Journal of medical virology · 2020Pooled it
- Role of a Synonymous Mutation at Codon 178 in P1 That Attenuates Potato Virus Y-Induced Tobacco Vein Necrosis and Its Application for Expressing Human Interferon.Molecular plant pathology · 2026Article
- The X Factor in Immunity: Sex Differences Shaped by the X Chromosome.Immunological reviews · 2026Review
- Pathogenesis and virulence of coronavirus disease: Comparative pathology of animal models for COVID-19.Virulence · 2024Review
- Harnessing the power of IFN for therapeutic approaches to COVID-19.Journal of virology · 2024Review
- SARS-CoV-2 immunity in animal models.Cellular & molecular immunology · 2024Review
- Global Perspective on COVID-19 Therapies, Cardiovascular Outcomes, and Implications for Long COVID: A State-of-the-Art Review.Journal of community hospital internal medicine perspectives · 2024Review
- Interferon regulatory factor 3 mediates effective antiviral responses to human coronavirus 229E and OC43 infection.Frontiers in immunology · 2023Article
- Eigenvalue analysis of SARS-CoV-2 viral load data: illustration for eight COVID-19 patients.International journal of data science and analytics · 2023Article
- Recent advances in small-molecular therapeutics for COVID-19.Precision clinical medicine · 2022Review
- Review of selected animal models for respiratory coronavirus infection and its application in drug research.Journal of medical virology · 2022Review
- SARS-CoV-2 pathogenesis.Nature reviews. Microbiology · 2022Review
- Interferon Control of Human Coronavirus Infection and Viral Evasion: Mechanistic Insights and Implications for Antiviral Drug and Vaccine Development.Journal of molecular biology · 2022Review
- The role of type I interferon in the treatment of COVID-19.Journal of medical virology · 2022Review
- Interferon α-2b spray shortened viral shedding time of SARS-CoV-2 Omicron variant: An open prospective cohort study.Frontiers in immunology · 2022Article
- Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus.Frontiers in cellular and infection microbiology · 2022Article
- SARS-CoV-2 Antiviral Therapy.Clinical microbiology reviews · 2021Review
- Susceptibility of rabbits to SARS-CoV-2.Emerging microbes & infections · 2021Article
179 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The primary cause of severe acute respiratory syndrome (SARS) is a newly discovered coronavirus. Replication of this SARS coronavirus (SCV) occurs mainly in the lower respiratory tract, and causes diffuse alveolar damage. Lack of understanding of the pathogenesis of SARS has prevented the rational development of a therapy against this disease. Here we show extensive SCV antigen expression in type 1 pneumocytes of experimentally infected cynomolgus macaques (Macaca fascicularis) at 4 d postinfection (d.p.i.), indicating that this cell type is the primary target for SCV infection early in the disease, and explaining the subsequent pulmonary damage. We also show that prophylactic treatment of SCV-infected macaques with the antiviral agent pegylated interferon-alpha (IFN-alpha) significantly reduces viral replication and excretion, viral antigen expression by type 1 pneumocytes and pulmonary damage, compared with untreated macaques. Postexposure treatment with pegylated IFN-alpha yielded intermediate results. We therefore suggest that pegylated IFN-alpha protects type 1 pneumocytes from SCV infection, and should be considered a candidate drug for SARS therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.